Episode Details
Back to Episodes
Medicare’s $50 Weight Loss Drug Pilot
Description
Starting July 2026, Medicare’s new GLP-1 Bridge program will offer weight loss meds like Wegovy and Zepbound for just $50 a month—changing lives for millions with obesity. But this isn’t permanent: it’s an 18-month test run with strict eligibility, including BMI thresholds or coexisting conditions. Crucially, the $50 doesn’t count toward your Part D spending limit, so even maxed-out patients pay it. Experts warn that without long-term coverage, patients risk regaining weight—and the future of access remains uncertain.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/3c7e24532ae97ea9